¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
È£Èí±âÁúȯ °Ë»ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°è È£Èí±âÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 2.8%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 77¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â °ÍÀº È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ±¹Á¦È£Èí±âÇÐȸ Æ÷·³¿¡ µû¸£¸é 2014³â Àü ¼¼°èÀûÀ¸·Î 2¾ï ¸í ÀÌ»óÀÌ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)À» ¾Î°í ÀÖÀ¸¸ç, 2¾ï 3,500¸¸ ¸íÀÌ Ãµ½ÄÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬°£ 5,000¸¸ ¸í ÀÌ»óÀÌ Á÷¾÷¼º ÆóÁúȯÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌó·³ ´ë»ó ȯÀÚ Àα¸°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COPD Áø´ÜÀ» À§ÇÑ ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ(CT)°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀÇ Ã¤ÅÃÀº ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COPDÀÇ ±Þ¼º±â ÀÇ·á °ü¸®ÀÇ ¶Ç ´Ù¸¥ ½Å±â¼úÀº ¿Ü·¡ ȯÀÚ ¸ð´ÏÅ͸µ¿¡ »ç¿ëµÇ´Â ¸Æ¹Ú »ê¼Ò ÃøÁ¤±âÀÔ´Ï´Ù. ±âµµ °ü¸®´Â COPDÀÇ °Ë»ç ¹× °ü¸®¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ ÃÖ±Ù ±â¼ú Çõ½ÅÀ¸·Î COPD °ü¸®¸¦ À§ÇÑ ºñħ½ÀÀû ±â°èÀû ȯ±â(NIV)ÀÇ »ç¿ëÀÌ 12.1% Áõ°¡Çß½À´Ï´Ù. ±â¼ú ¹ßÀü°ú ÇÔ²² È£Èí±âÁúȯ °Ë»ç/Áø´Ü ½ÃÀå¿¡¼ µðÁöÅÐ ¹æ»ç¼± ÃÔ¿µ(X-ray)°ú ÷´Ü ÈÞ´ë¿ë ÆóȰ·®°è »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
È£Èí±âÁúȯ °Ë»ç ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â µÎ °¡Áö ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
- Á¦Ç°º°·Î´Â Çõ½ÅÀûÀÎ ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú äÅÃÀ¸·Î ÀÎÇØ ¿µ»ó °Ë»ç°¡ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- ¿ëµµº°·Î´Â °áÇÙÀÌ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀÎÇØ 2022³â °¡Àå Å« ½ÃÀåÀ¸·Î ºÎ»óÇÒ Àü¸ÁÀÔ´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÐ¾ß°¡ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÔ¿ø Áõ°¡¿Í º´¿ø Ä¡·á ¼±È£µµ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â 2022³â È£Èí±âÁúȯ °Ë»ç ½ÃÀåÀ» µ¶Á¡ÇßÀ¸¸ç, COPD, õ½Ä µî È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡, Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¶±â Áø´ÜÀÇ ÀÌÁ¡¿¡ ´ëÇÑ È¯ÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁø °ÍÀÌ ¿ì¼¼ÇÑ ¿äÀÎÀÔ´Ï´Ù.
- ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú COPD ¹× õ½Ä°ú °°Àº È£Èí±âÁúȯ¿¡ ´ëÇÑ »õ·Î¿î Áø´Ü ±â¼úÀÇ °¡¿ë¼º¿¡ ´ëÇÑ È¯ÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö´Â µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
- ÀÌ ½ÃÀå¿¡¼ °æÀïÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â Becton Dickinson(Carefusion Corporation), Koninklijke Philips N.V.(Respironics), ResMed Company, Fischer &Paykel, Medtronic µîÀÌ ÀÖÁö¸¸, ÀÌ¿¡ ±¹ÇѵÇÁö´Â ¾Ê½À´Ï´Ù. ÀÌµé ±â¾÷Àº È£Èí±âÁúȯ Áø´Ü ½ÃÀå¿¡¼ Á¤±³ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ º¸À¯Çϰí ÀÖÀ¸¸ç, ½ÃÀå¿¡¼ °·ÂÇÑ ºê·£µåÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå È£Èí±âÁúȯ °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå È£Èí±âÁúȯ °Ë»ç : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ¿µ»ó °Ë»ç
- ¿µ»ó °Ë»ç ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- È£Èí ÃøÁ¤ Àåºñ
- È£Èí ÃøÁ¤ Àåºñ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- Ç÷¾×°¡½º °Ë»ç
- Ç÷¾×°¡½º °Ë»ç ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
Á¦5Àå È£Èí±âÁúȯ °Ë»ç : Àû¿ë ÃßÁ¤¡¤µ¿Ç⠺м®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ¸¸¼ºÆó¼â¼ºÆóÁúȯ
- Æó¾Ï
- õ½Ä
- °áÇÙ
- ±âŸ
Á¦6Àå È£Èí±âÁúȯ °Ë»ç : ÃÖÁ¾ »ç¿ë ÃßÁ¤¡¤µ¿Ç⠺м®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- È£Èí±âÁúȯ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- º´¿ø
- º´¿ø ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- ÀÇ»ç Áø·á¼Ò
- ÀÇ»ç Áø·á¼Ò ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- ÀÓ»ó °Ë»ç½Ç
- ÀÓ»ó °Ë»ç ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼ 2030³â±îÁö
Á¦7Àå È£Èí±âÁúȯ °Ë»ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° È£Èí±âÁúȯ °Ë»ç ½ÃÀå : ¸¶ÄÏÇ÷¹À̽ºÀÇ Áß¿äÇÑ Æ÷ÀÎÆ®
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- Abbott
- BD
- Koninklijke Philips N.V.
- ResMed
- Fisher & Paykel Appliances Ltd
- Medtronic
- BIOMERIEUX
- Carestream Health
- SDI Diagnostics
- Siemens Healthcare GmbH
ksm 23.10.31
Respiratory Disease Testing Market Growth & Trends:
The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is driven by the rising prevalence of respiratory diseases. As per Forum of International Respiratory Societies, more than 200 million people across the globe suffered from Chronic Obstructive Pulmonary Disease (COPD) and 235 million suffered from asthma in 2014. In addition, the source stated that more than 50 million people struggle with occupational lung diseases annually. Thus, constantly growing target patient population is anticipated to drive the growth.
The adoption of innovative technologies, such as Computed Tomography (CT), for COPD diagnosis is expected to drive the growth. The other new technology in acute medical management of COPD is pulse oximeter that is used for outpatient monitoring. Airway management plays a main role in testing and management of COPD. Also, with recent technological innovations, there has been a 12.1 % increase in the use of Noninvasive Mechanical Ventilation (NIV) for management of COPD. Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
Respiratory Disease Testing Market Report Highlights:
- Growing prevalence of respiratory diseases and rapid technological advancements are two of the major factors expected to propel the market growth
- Based on products, imaging tests held the largest share in 2022 due to rapid development and adoption of innovative technologies
- Based on application, tuberculosis was the largest market in 2022 owing to rising prevalence of the disease globally
- Based on end-use, hospitals segment held the largest share in 2022 and is anticipated to grow over the forecast period due to an increase in hospitalization and a growing preference for hospital treatment
- North America dominated the respiratory disease testing market in 2022. Growing prevalence of respiratory diseases such as COPD, & asthma, increasing demand for early diagnosis, and rising awareness amongst patients about the benefits of early diagnosis are responsible for the dominance
- Asia Pacific region is expected to grow at the fastest rate during the forecast period. This growth can be attributed to various factors, such as improving healthcare infrastructure and increasing patient awareness regarding the availability of new diagnostic techniques for respiratory diseases, such as COPD & asthma
- Some of the major players competing in this market include, but are not limited to, Becton Dickinson (Carefusion Corporation); Koninklijke Philips N.V. (Respironics); ResMed Company; Fischer & Paykel; and Medtronic. These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Application
- 1.1.3. End-use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application outlook
- 2.2.3. End-use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Respiratory Disease Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Respiratory Disease Testing Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic Landscape
Chapter 4. Respiratory Disease Testing: Product Estimates & Trend Analysis
- 4.1. Respiratory Disease Testing Market: Key Takeaways
- 4.2. Respiratory Disease Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Imaging Tests
- 4.3.1. Imaging tests market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Respiratory Measurement devices
- 4.4.1. Respiratory measurement devices market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Blood Gas Test
- 4.5.1. Blood gas test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Others
- 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Respiratory Disease Testing: Application Estimates & Trend Analysis
- 5.1. Respiratory Disease Testing Market: Key Takeaways
- 5.2. Respiratory Disease Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Chronic Obstructive Pulmonary Disease
- 5.3.1. Chronic obstructive pulmonary disease market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Lung Cancer
- 5.4.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Asthma
- 5.5.1. Asthma market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Tuberculosis
- 5.6.1. Tuberculosis market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Respiratory Disease Testing: End-use Estimates & Trend Analysis
- 6.1. Respiratory Disease Testing Market: Key Takeaways
- 6.2. Respiratory Disease Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Hospital
- 6.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Physicians Clinic
- 6.4.1. Physician clinic market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Clinical Laboratories
- 6.5.1. Clinical laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Respiratory Disease Testing Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Respiratory Disease Testing Market by Region: Key Marketplace Takeaway
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Sweden
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Norway
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. Saudi Arabia
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Abbott
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic Initiatives
- 8.2.2. BD
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Koninklijke Philips N.V.
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. ResMed
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Fisher & Paykel Appliances Ltd
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Medtronic
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. BIOMERIEUX
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Carestream Health
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. SDI Diagnostics
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Siemens Healthcare GmbH
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives